A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens: Omalizumab treatment in real life
2018
Introduction
Omalizumab has been available for treatment of allergic asthma for more than a decade and thus, its efficacy in routine treatment was of interest to evaluate. Basophil allergen threshold sensitivity (CD‐sens) has been shown to correlate with the bronchial allergen threshold sensitivity and can be used to objectively measure omalizumab treatment efficacy. We aimed to evaluate the effect of omalizumab treatment of allergic asthma by CD‐sens, as an objective marker of the IgE‐mediated inflammation, and related to SPT, spirometry, FeNO, Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
29
References
5
Citations
NaN
KQI